Last Updated : March 28, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type Sort descending | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Avastin | Bevacizumab | Platinum Resistant Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Kyprolis (with lenalidomide) | Carfilzomib (with lenalidomide) | Multiple Myeloma | Reimburse with clinical criteria and/or conditions | Complete | ||
Zepatier | Elbasvir/grazoprevir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
Fycompa | Perampanel | Epilepsy, primary generalized tonic-clonic seizures | Reimburse with clinical criteria and/or conditions | Complete | ||
Opdivo | Nivolumab | Metastatic non small cell lung cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Blincyto | Blinatumomab | Acute Lymphoblastic Leukemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Jakavi | Ruxolitinib | Polycythemia vera | Reimburse with clinical criteria and/or conditions | Complete | ||
Praluent | Alirocumab | Primary hypercholesterolemia (non-familial and heterozygous familial), mixed dyslipidemia | Reimburse with clinical criteria and/or conditions | Complete | ||
Imbruvica | Ibrutinib | Mantle Cell Lymphoma (relapsed/refractory) | Reimburse with clinical criteria and/or conditions | Complete | ||
Kuvan | Sapropterin dihydrochloride | Phenylketonuria (PKU) | Reimburse with clinical criteria and/or conditions | Complete |